Shopping Cart
Remove All
Your shopping cart is currently empty
Catumaxomab (Synonyms: LP-000, LP000)
Catalog No. T78307 Copy Product Info
🥰Excellent
Catumaxomab （LP-000） is a rat-mouse hybrid lgG2 monoclonal and bispecific antibody that binds to the antigens CD3 and EpCAM (Epithelial Cell Adhesion Molecule) for the treatment of malignant ascites in cancer patients.
Catumaxomab
Copy Product Info🥰Excellent
Catalog No. T78307
Synonyms LP-000, LP000
Catumaxomab （LP-000） is a rat-mouse hybrid lgG2 monoclonal and bispecific antibody that binds to the antigens CD3 and EpCAM (Epithelial Cell Adhesion Molecule) for the treatment of malignant ascites in cancer patients.
Catumaxomab
Cas No. 509077-98-9
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $328 | - | In Stock | |
| 5 mg | $859 | - | In Stock | |
| 10 mg | $1,380 | - | In Stock | |
| 25 mg | $1,980 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:>95.0% (SDS-PAGE)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Catumaxomab （LP-000） is a rat-mouse hybrid lgG2 monoclonal and bispecific antibody that binds to the antigens CD3 and EpCAM (Epithelial Cell Adhesion Molecule) for the treatment of malignant ascites in cancer patients. |
| In vitro | Catumaxomab inhibits the growth of FaDu tumor spheroids co-cultured with PBMCs in a dose-dependent manner when treated at concentrations ranging from 0 to 5 ng/mL for 3 to 7 days [1]. |
| In vivo | Catumaxomab was administered intraperitoneally to patients with EpCAM-positive cancers and malignant ascites on days 0, 3, 7, and 10 at escalating doses of 10, 20, 50, and 150 μg, respectively. The treatment significantly prolonged puncture-free survival, reduced the number of EpCAM-positive tumor cells and VEGF levels in ascitic fluid, and enhanced the activation of CD4⁺ and CD8⁺ T cells [2]. |
| Synonyms | LP-000, LP000 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | EpCAM/TROP1/CD326 & CD3E |
| Molecular Weight | 146.73 kDa |
| Cas No. | 509077-98-9 |
| Isotype | IgG2a-kappa/IgG2b-lambda |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Catumaxomab | purchase Catumaxomab | Catumaxomab cost | order Catumaxomab | Catumaxomab in vivo | Catumaxomab in vitro | Catumaxomab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.